{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:15:15Z","timestamp":1793042115912,"version":"4.5.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tuck Family Scholarship Lake Imaging"},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1040978"],"award-info":[{"award-number":["1040978"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0210891","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T18:27:30Z","timestamp":1550168850000},"page":"e0210891","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial\u2014Clinical outcomes and molecular determinants of response"],"prefix":"10.1371","volume":"14","author":[{"given":"Caitlin","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Muscat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violet","family":"Mukaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chisanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6936-0942","authenticated-orcid":true,"given":"Ian","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Baron-Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Lindeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Khasraw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"JA Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4081\/oncol.2017.324","article-title":"The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer","volume":"11","author":"AB Castrellon","year":"2017","journal-title":"Oncol Rev"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease","volume":"13","author":"G Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"7605","key":"ref4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"S Nik-Zainal","year":"2016","journal-title":"Nature"},{"issue":"7403","key":"ref5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature11143","article-title":"Whole-genome analysis informs breast cancer response to aromatase inhibition","volume":"486","author":"MJ Ellis","year":"2012","journal-title":"Nature"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nm.3886","article-title":"Subclonal diversification of primary breast cancer revealed by multiregion sequencing","volume":"21","author":"LR Yates","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/jnci\/djq524","article-title":"Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer","volume":"103","author":"T Iwamoto","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1158\/1078-0432.CCR-11-2762","article-title":"Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer","volume":"18","author":"AM Gonzalez-Angulo","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets","volume":"4","author":"JM Balko","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/annonc\/mdw434","article-title":"Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial","volume":"28","author":"W Shi","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","article-title":"Genomic evolution of breast cancer metastasis and relapse","volume":"32","author":"LR Yates","year":"2017","journal-title":"Cancer Cell"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"e1002193","DOI":"10.1371\/journal.pmed.1002193","article-title":"Predictors of chemosensitivity in triple negative breast cancer: An integrated genomic analysis","volume":"13","author":"T Jiang","year":"2016","journal-title":"PLoS Med"},{"issue":"9938","key":"ref13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"P Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/sj.bjc.6602950","article-title":"Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma","volume":"94","author":"RL Jones","year":"2006","journal-title":"Br J Cancer"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1586\/era.12.62","article-title":"Primary systemic therapy in HER2-amplified breast cancer: A clinical review","volume":"12","author":"M Khasraw","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3816\/CBC.2010.n.011","article-title":"A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil\/epirubicin\/cyclophosphamide in locally advanced breast cancer","volume":"10","author":"A Robidoux","year":"2010","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1093\/nar\/gkt214","article-title":"The Subread aligner: Fast, accurate and scalable read mapping by seed-and-vote","volume":"41","author":"Y Liao","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"ref18","unstructured":"Shi WLY. Subread 2018 [cited 2018 August 1]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/subread.sourceforge.net\/\" xlink:type=\"simple\">http:\/\/subread.sourceforge.net\/<\/ext-link>."},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl variant effect predictor","volume":"17","author":"W McLaren","year":"2016","journal-title":"Genome Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2105-13-134","article-title":"Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction","volume":"13","author":"J Ye","year":"2012","journal-title":"BMC Bioinformatics"},{"key":"ref21","unstructured":"OligoAnalyzer 3.1 [cited 2018 March 1]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/sg.idtdna.com\/calc\/analyzer\" xlink:type=\"simple\">https:\/\/sg.idtdna.com\/calc\/analyzer<\/ext-link>."},{"key":"ref22","unstructured":"Kent J. [cited 2018 March 1]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/genome.ucsc.edu\/cgi-bin\/hgPcr\" xlink:type=\"simple\">https:\/\/genome.ucsc.edu\/cgi-bin\/hgPcr<\/ext-link>."},{"key":"ref23","unstructured":"CallableLoci 2018 [cited 2018 March 1]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/software.broadinstitute.org\/gatk\/documentation\/tooldocs\/3.8-0\/org_broadinstitute_gatk_tools_walkers_coverage_CallableLoci.php\" xlink:type=\"simple\">https:\/\/software.broadinstitute.org\/gatk\/documentation\/tooldocs\/3.8-0\/org_broadinstitute_gatk_tools_walkers_coverage_CallableLoci.php<\/ext-link>."},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"W Huang da","year":"2009","journal-title":"Nat Protoc"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nar\/gkn923","article-title":"Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists","volume":"37","author":"W Huang da","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"E Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13059-016-0893-4","article-title":"DeconstructSigs: Delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution","volume":"17","author":"R Rosenthal","year":"2016","journal-title":"Genome Biol"},{"key":"ref28","unstructured":"COSMIC Signatures of Mutational Processes in Cancer [cited 2018 June 1]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/cancer.sanger.ac.uk\/cosmic\/signatures\" xlink:type=\"simple\">https:\/\/cancer.sanger.ac.uk\/cosmic\/signatures<\/ext-link>."},{"key":"ref29","article-title":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM","author":"H Li","year":"2013","journal-title":"arXiv preprint arXiv:13033997"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"11.0.1","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high-confidence variant calls: The genome analysis toolkit best practices pipeline","volume":"43","author":"GA Auwera","year":"2013","journal-title":"Curr Protoc Bioinformatics"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"DC Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"ref32","unstructured":"Flensburg C. superFreq 2018 [cited 2018 June]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/github.com\/ChristofferFlensburg\/superFreq\" xlink:type=\"simple\">https:\/\/github.com\/ChristofferFlensburg\/superFreq<\/ext-link>."},{"issue":"15","key":"ref33","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"G von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1158\/1078-0432.CCR-16-2810","article-title":"Mutational signatures in breast cancer: The problem at the DNA level","volume":"23","author":"S Nik-Zainal","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref35","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"P Polak","year":"2017","journal-title":"Nat Genet"},{"issue":"7","key":"ref36","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","article-title":"APOBEC enzymes: Mutagenic fuel for cancer evolution and heterogeneity","volume":"5","author":"C Swanton","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"e1002204","DOI":"10.1371\/journal.pmed.1002204","article-title":"The subclonal architecture of metastatic breast cancer: Results from a prospective community-based rapid autopsy program &quot;CASCADE&quot;","volume":"13","author":"P Savas","year":"2016","journal-title":"PLoS Med"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10549-017-4624-7","article-title":"Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1\/2 mutation-associated breast cancer","volume":"168","author":"ML Telli","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/annonc\/mdx821","article-title":"Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)","volume":"29","author":"P Sharma","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1574892813666171204094822","article-title":"PARP inhibitors in epithelial ovarian cancer","volume":"13","author":"KN Taylor","year":"2018","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"17","key":"ref41","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","article-title":"TBCRC009: A multicenter Phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer","volume":"33","author":"SJ Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15","key":"ref42","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"ML Telli","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00031","article-title":"Homologous recombination deficiency in breast cancer: A clinical review","author":"WDd Brok","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"ref44","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"H Davies","year":"2017","journal-title":"Nat Med"},{"issue":"24","key":"ref45","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1158\/1078-0432.CCR-17-1941","article-title":"Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer","volume":"23","author":"EY Zhao","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ref46","first-page":"2505","article-title":"Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer","volume":"61","author":"S Geisler","year":"2001","journal-title":"Cancer Res"},{"issue":"7643","key":"ref47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nature21356","article-title":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","volume":"543","author":"KM Turner","year":"2017","journal-title":"Nature"},{"issue":"23","key":"ref48","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1242\/jcs.169730","article-title":"ATM and ATR signaling at a glance","volume":"128","author":"P Awasthi","year":"2015","journal-title":"J Cell Sci"},{"issue":"2","key":"ref49","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ng.3779","article-title":"SWI\/SNF complex in cancer","volume":"49","author":"C Lu","year":"2017","journal-title":"Nat Genet"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/modpathol.2011.161","article-title":"Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma","volume":"25","author":"A Katagiri","year":"2012","journal-title":"Mod Pathol"},{"issue":"14","key":"ref51","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/onc.2009.4","article-title":"The SWI\/SNF complex and cancer","volume":"28","author":"D Reisman","year":"2009","journal-title":"Oncogene"},{"issue":"7","key":"ref52","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1535-7163.MCT-15-0554","article-title":"synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with dasatinib","volume":"15","author":"RE Miller","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"CT Williamson","year":"2016","journal-title":"Nat Commun"},{"issue":"6377","key":"ref54","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"D Miao","year":"2018","journal-title":"Science"},{"issue":"6377","key":"ref55","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing","volume":"359","author":"D Pan","year":"2018","journal-title":"Science"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0210891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T20:08:04Z","timestamp":1720987684000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0210891"}},"subtitle":[],"editor":[{"given":"Giandomenico","family":"Roviello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0210891","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,14]]}}}